Last updated on July 2019

Study of Sustained Benefit of Erenumab in Adult Episodic Migraine Patients

Brief description of study

The primary objective is to demonstrate the superiority of subcutaneous erenumab compared to oral prophylactic(s) on sustained benefit defined as % subjects completing one-year on the randomized treatment and achieving at least a 50% reduction from baseline in monthly migraine days at month 12.

Clinical Study Identifier: NCT03927144

Find a site near you

Start Over


Watertown, MA United States
  Connect »